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Neuroendocrine tumours (NETs) have distinct biological
and clinical characteristics, in particular a high density
of somatostatin receptors at the cell membrane [1]. It is
this property that allows the use of radiolabelled soma-
tostatin analogues for imaging of these tumours. Impor-
tantly, somatostatin receptor PET/CT imaging (e.g.
68Ga-DOTATOC, 68Ga-DOTATATE, 68Ga-DOTANOC)
is superior to somatostatin receptor scintigraphy includ-
ing SPECT/CT [2] and 18F-DOPA PET/CT [3] in the
detection of gastroenteropancreatic neuroendocrine
tumours (GEP NETs).
NETs, however, have a wide range of cellular differ-
entiation. 18F-FDG PET/CT is of limited value in well-
differentiated NETs but of high value in poorly differ-
entiated NETs. Somatostatin receptor PET/CT shows
contrary results [4]. As both 18F-FDG PET/CT and
somatostatin receptor PET/CT exploit distinct tumour
characteristics they are complementary for tumour
staging.
Small insulinomas are difficult to detect with 18F-FDG
PET/CT, somatostatin receptor PET/CT, 18F-DOPA PET/
CT and morphological imaging. Targeting of Glucagon-
like peptide-1 receptors using radiolabelled exendin-4 has
shown to be highly effective in the detection of these
tumours [5].
Clinical studies have shown higher tumour uptake of
radiolabelled somatostatin receptor antagonists than
somatostatin receptor agonists [6]. As a result radiola-
belled somatostatin receptor antagonists may have a
significant impact on imaging of NETs.
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